39,667 Johnson & Johnson $JNJ Shares Sold by Axxcess Wealth Management LLC

Key Points

• Axxcess Wealth Management cut its Johnson & Johnson stake by 44.1% in the third quarter, selling 39,667 shares and retaining 50,379 shares valued at approximately $13.3 million. Institutional investors collectively own 69.55% of J&J.
• Johnson & Johnson reported quarterly EPS of $2.59, beating estimates by $0.06, while revenue rose 5.9% year over year to $25.4 billion. The company maintained 2026 EPS guidance of $11.05–$11.15 and declared a quarterly dividend of $1.34 per share, yielding about 2.0% annually.
• The stock has a “Moderate Buy” consensus rating with an average price target of $275.92, but analysts remain divided due to its premium valuation, MedTech execution concerns and falling earnings estimates. Recent insider selling and a reported collapse of a potential orthopedics combination add further caution.

Axxcess Wealth Management LLC lessened its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 44.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 50,379 shares of the company's stock after selling 39,667 shares during the period. Axxcess Wealth Management LLC's holdings in Johnson & Johnson were worth $13,337,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Outlook Capital Management LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $28,000. Matrix Trust Co raised its position in shares of Johnson & Johnson by 56.2% in the second quarter. Matrix Trust Co now owns 150 shares of the company's stock worth $38,000 after acquiring an additional 54 shares during the period. Montgomery Financial Services LLC acquired a new position in shares of Johnson & Johnson in the second quarter worth about $43,000. Polaris Financial Partners purchased a new stake in shares of Johnson & Johnson during the 3rd quarter worth about $56,000. Finally, Bullseye Investment Management LLC purchased a new stake in shares of Johnson & Johnson during the 2nd quarter worth about $63,000. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $264.13 on Friday. The stock has a market cap of $635.85 billion, a PE ratio of 40.02, a price-to-earnings-growth ratio of 2.65 and a beta of 0.21. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07. The firm has a fifty day moving average price of $265.64 and a 200 day moving average price of $250.21. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.81.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. The business had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company's revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period last year, the firm posted $2.80 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, sell-side analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a dividend of $1.34 per share. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio is 81.21%.

Insider Activity

In other Johnson & Johnson news, EVP Elizabeth Forminard sold 15,918 shares of the company's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $257.00, for a total value of $4,090,926.00. Following the sale, the executive vice president owned 16,994 shares of the company's stock, valued at approximately $4,367,458. This represents a 48.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the completion of the sale, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. The trade was a 7.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 64,515 shares of company stock worth $17,271,766 in the last 90 days. 0.16% of the stock is currently owned by corporate insiders.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The United Kingdom approved J&J’s oral psoriasis treatment, expanding the company’s commercial opportunity in a major market and strengthening its immunology pipeline. UK approves J&J's oral psoriasis pill
• Positive Sentiment: J&J reported first real-world data for its VARIPULSE Pro platform and 12-month outcomes for the OMNYPULSE platform in atrial-fibrillation treatment. The results could support adoption of its MedTech portfolio and help offset weakness in other device businesses. J&J reports VARIPULSE Pro and OMNYPULSE data
• Positive Sentiment: J&J has benefited from investor rotation into defensive healthcare and consumer-staples companies amid broader large-cap weakness, reinforcing demand for its relatively stable earnings and dividend profile. Defensive stocks attract buyers
• Neutral Sentiment: J&J’s implied fair value was raised from $270.59 to $279.41 per share, but analyst views remain divided. Supporters cite earnings resilience and the drug pipeline, while others point to valuation, MedTech execution risk and possible dilution from recent deals. J&J fair value adjustment
• Negative Sentiment: A proposed combination involving J&J’s orthopedics business and Smith & Nephew reportedly collapsed over a leadership dispute. The development removes potential strategic benefits and may raise questions about execution, although Smith & Nephew declined to comment. Orthopedics merger reportedly collapsed
• Negative Sentiment: J&J reclaimed its 50-day moving average, but falling earnings estimates, a premium valuation and weakness in MedTech are limiting the bullish technical signal. Erste Group also downgraded the shares to “Hold,” adding to near-term investor caution. J&J stock outlook and valuation concerns

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent analyst reports. Morgan Stanley cut their price target on Johnson & Johnson from $294.00 to $292.00 and set an "overweight" rating for the company in a research note on Thursday, October 15th. Raymond James Financial set a $280.00 price target on Johnson & Johnson in a research report on Monday, August 3rd. Johnson Rice downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday. Argus set a $300.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 29th. Finally, Freedom Capital upgraded shares of Johnson & Johnson from a "hold" rating to a "strong-buy" rating in a research report on Thursday, July 16th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Company Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.